Effects of Fenofibrate on the Safety, Toleration and Efficacy Biomarkers of CP-742,033

This study has been withdrawn prior to enrollment.

Sponsor:

Information provided by (Responsible Party):

Pfizer

ClinicalTrials.gov Identifier:

NCT00376285

First received: September 13, 2006

Last updated: April 21, 2015

Last verified: April 2015

History of Changes

Purpose

The purpose of this study is to determine whether fenofibrate effects the toleration, safety, or efficacy biomarkers of CP-742,033, a drug being developed for the treatment of obesity.

Condition	Intervention	Phase
Obesity	Drug: CP-742,033 Drug: Fenofibrate	Phase 1


Study Type:	Interventional
Study Design:	Allocation: Randomized Intervention Model: Parallel Assignment Masking: Single Primary Purpose: Treatment
Official Title:	A Phase 1, Randomized, Investigator and Subject Blind, Sponsor Open Study to Determine the Effects of Fenofibrate on the Safety, Toleration and Efficacy Biomarkers of CP-742,033 When Co-Administered in Otherwise Healthy Obese Adult Subjects

Resource links provided by NLM:

Drug Information available for: Fenofibrate

U.S. FDA Resources

Further study details as provided by Pfizer:

Primary Outcome Measures:

Toleration and safety

Secondary Outcome Measures:

Efficacy biomarkers, serum lipids


Enrollment:	0
Study Start Date:	November 2006

Eligibility


Ages Eligible for Study:	18 Years to 65 Years (Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

BMI of 30-40 kg/m2

Exclusion Criteria:

Women of childbearing potential

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00376285

Sponsors and Collaborators

Pfizer

Investigators


Study Director:	Pfizer CT.gov Call Center	Pfizer

More Information

Additional Information:

To obtain contact information for a study center near you, click here. This link exits the ClinicalTrials.gov site


Responsible Party:	Pfizer
ClinicalTrials.gov Identifier:	NCT00376285 History of Changes
Other Study ID Numbers:	A5431015
Study First Received:	September 13, 2006
Last Updated:	April 21, 2015

Additional relevant MeSH terms:


Fenofibrate Hypolipidemic Agents Antimetabolites Molecular Mechanisms of Pharmacological Action Lipid Regulating Agents

ClinicalTrials.gov processed this record on September 21, 2017

To Top